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Group 2 innate lymphoid cells (ILC2s) are involved in human diseases, such as allergy, atopic
dermatitis and nasal polyposis, but their function in human cancer remains unclear. Here we
show that, in acute promyelocytic leukaemia (APL), ILC2s are increased and hyper-activated
through the interaction of CRTH2 and NKp30 with elevated tumour-derived PGD2 and B7H6,
respectively. ILC2s, in turn, activate monocytic myeloid-derived suppressor cells (M-MDSCs)
via IL-13 secretion. Upon treating APL with all-trans retinoic acid and achieving complete
remission, the levels of PGD2, NKp30, ILC2s, IL-13 and M-MDSCs are restored. Similarly,
disruption of this tumour immunosuppressive axis by speciﬁcally blocking PGD2, IL-13 and
NKp30 partially restores ILC2 and M-MDSC levels and results in increased survival. Thus,
using APL as a model, we uncover a tolerogenic pathway that may represent a relevant
immunosuppressive, therapeutic targetable, mechanism operating in various human tumour
types, as supported by our observations in prostate cancer.
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Innate lymphoid cells (ILCs) are a family of lymphocytesinvolved in the initiation, regulation and resolution phasesof inﬂammatory processes1, 2. ILCs differentiate into ILC1,
ILC2 and ILC3 with distinct transcriptional regulation and
functional attributes, which mirror the T-helper 1 (Th1), Th2 and
Th17/Th22 CD4+ lymphocytes, respectively. However, unlike
T cells, ILCs lack somatically rearranged antigen receptors and
lineage markers (Lin−)3, 4.
Originally described in murine models, ILC2 are best deﬁned
by the constitutive expression of the interleukin (IL)-7 receptor
alpha chain (CD127) and the prostaglandin D2 (PGD2)
receptor, CRTH25. ILC2 differentiation is dependent on the
transcription factors GATA36 and RORα7. Once activated by
alarmins (e.g., IL-33, IL-25 and thymic stromal lymphopoietin
(TSLP)) ILC2s rapidly produce effector cytokines, mostly IL-5,
IL-9 and IL-138. Moreover, in vitro treatment with PGD2
has been shown to induce the chemotaxis of and IL-13
production by ILC2s9, whereas type I interferons (IFN) (mainly
IFN-β), IFN-γ, IL-2710, 11 and prostaglandin I2 (PGI2)
restrain ILC2’s function and suppress type 2 immunity12.
Beside soluble mediators, ILC2s also rely on cell-cell contacts
for their activation. In that context, expression of the type I
Ig-like transmembrane natural cytotoxicity receptor (NCR)
NKp30 on human ILC2s was shown to trigger the secretion
of type 2 cytokines upon in vitro binding to one of its ligands,
B7H613.
Dysregulation or chronic activation of ILC2s has been reported
in pathologic conditions, such as allergy, atopic dermatitis and
nasal polyposis14. However, ILC2s’ function in tumour immune
regulation remains largely unknown. Studies in mouse models
show that ILC2s are associated with reduction in metastases in a
lung metastatic tumour model, through the regulation of eosi-
nophil recruitment15. In addition, ILC2 were shown to induce
tumour cell apoptosis in response to locally secreted IL-3316.
By contrast, the IL-33/IL-33 receptor (ST2) axis inhibits tumour
surveillance in a breast carcinoma model by interacting with
myeloid-derived suppressor cells (MDSC)17, and promotes cho-
langiocyte proliferation and epithelial hyperplasia in a cho-
langiocarcinoma model18. However, the ILC2 contribution, if
any, to human tumour immune responses remains unknown,
with only one report showing elevated frequencies of circulating
ILC2s (deﬁned as Lin−ICOS+IL17RB+ cells) in gastric cancer
patients19.
Among acute myeloid leukaemia (AML), acute promyelocytic
leukaemia (APL) is a distinct clinico-pathologic entity char-
acterized by the t(15;17) translocation that leads to an arrest of
myeloid differentiation at the promyelocytic stage. The majority
of APL patients achieve remission upon treatment by all-trans
retinoic acid (ATRA) that causes the differentiation of the leu-
kaemic clone to a post-mitotic state20.
Here we show that ILC2s are the major ILC subtype present in
human APL. Given the unique setting of a malignancy deﬁni-
tively cured by targeted therapies, we use APL as a model to
investigate the involvement of ILC2 in human tumour estab-
lishment and clearance. We unravel a tumour immunosuppres-
sive axis initiated by APL blasts. Via the release of PGD2 and
the expression of B7H6, APL blasts engage CRTH2+NKp30+
ILC2s and induce their activation and IL-13 release, which in
turn drives the expansion and the immune suppressive function
of IL-13Rα1+ monocytic myeloid-derived suppressor cells
(M-MDSCs). Disruption of this tumour immunosuppressive axis
by speciﬁcally blocking PGD2, IL-13 and NKp30 partially
normalizes ILC2 and M-MDSC levels and results in increased
survival in leukaemic mice. Our additional results in prostate
cancer suggest that the same axis may be activated also in solid
tumours. As the identiﬁed pathways can be druggable, this axis
may have a therapeutic value in different human solid and hae-
matologic malignancies, beyond APL.
Results
ILC2s are signiﬁcantly increased in human APL. Here we
measured the relative and absolute numbers of ILCs in peripheral
blood of 22 APL patients at diagnosis. Whereas total ILCs were
comparable between healthy donors and APL patients (Supple-
mentary Fig. 1a and Fig. 1a–c), the latter were characterized by a
robust ILC1 and ILC2 enrichment in the periphery (Fig. 1d–f).
However, we and others previously reported in other AML sub-
types a profound ILC dysregulation affecting the ILC1 and
ILC3 subsets21, 22, with an expansion in ILC1. Since ILC1 is
identiﬁed in human as ILCs negative for CRTH2, cKit and CD56
expression, we tested whether, in APL patients, the ILC1 fraction
comprised also undifferentiated ILC precursors, recently deﬁned
by others as CD5+CD1a− ILCs. Within the ILC1 subset, we
observed elevated levels of ILC precursors in the bone marrow of
patients compared to healthy donors (Supplementary Fig. 1b, c).
On the contrary, ILC2 enrichment speciﬁcally distinguishes APL
from the other AML subtypes that do not show alterations in the
ILC2 compartment21, 22. Therefore, APL represents a unique
setting to delineate the cellular and molecular bases of ILC2
expansion in human tumours.
Interestingly, we found no difference in the ILC2 distribution
in the bone marrow (BM) between APL patients and healthy
donors (Fig. 1g, h). Still, the analysis of paired BM and peripheral
blood (PB) APL samples revealed a selective increase in ILC2s in
the periphery (Fig. 1i, j). To understand whether the accumula-
tion of ILC2s in the periphery was due to increased proliferation,
extended survival or both, we measured the expression of Ki-67
and Bcl-2 in these cells. Peripheral ILC2s of APL patients showed
similar levels of Bcl-2 (Supplementary Fig. 1d) and increased
levels of Ki-67 when compared with either peripheral ILC2s of
healthy donors or BM ILC2s of APL patients (Fig. 1k).
These ﬁndings suggest that in APL patients the increased levels
of circulating ILC2s are mainly due to peripheral expansion.
PGD2 and NKp30-B7H6 binding drive IL-13 secretion by
ILC2s. ILCs exert their main functions through effector cytokines
and, among them, ILC2s are mainly involved in the production of
type 2 cytokines, including IL-13. Consistent with an increased
frequency of peripheral ILC2s, serum concentrations of
circulating IL-13 were signiﬁcantly higher in APL patients than
healthy donors, while the serum concentrations of circulating
IFN-γ and IL-17A were comparable (Fig. 2a). Supporting an
important role for ILC2s as the source of circulating IL-13, the
levels of ILC2-derived IL-13 in response to co-culture with APL
cell lines were signiﬁcantly higher in ILCs from APL patients than
controls, while no difference was observed for IFN-γ and IL-17A
(Fig. 2b, c). Since IL-13 is also secreted by CD4+ Th2 and
NKT cells, we assessed by the expression of prototypic surface
markers the T-helper subset distribution in APL patients as well
as the presence of NKT cells. We found no difference in the levels
of CD4+ Th2 cells and NKT cells in patients compared to healthy
controls (Supplementary Fig. 2a, b). When incubated with auto-
logous primary blasts, ILC2 from APL patients, and not NKT nor
Th2 cells from either group, produced higher amounts of IL-13
than ILC2s from healthy donors, and were the population with
the highest capacity of producing IL-13 in response to blasts
(Fig. 2d, e).
Next, we asked why circulating ILC2s produce higher amounts
of IL-13 in response to APL blasts. Since IL-13 production can be
triggered through the engagement of NKp30 on ILC2s by its
ligand B7H6 on target cells13, we assessed the expression of B7H6
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and NKp30 in human APL blasts and ILC2s, respectively. Both
the established APL cell line NB4, as well as the HL60 line,
expressed high levels of the NKp30 ligand B7H6 (Fig. 2f, g).
Furthermore, to ascertain whether the NKp30-B7H6 interaction
could also occur in vivo, we screened primary APL blasts for
the expression of B7H6. Peripheral APL blasts expressed
distinctly higher levels of B7H6 than their counterparts in the
BM (Fig. 2h, i). Importantly, peripheral blood ILC2s from APL
patients expressed higher levels of NKp30 when compared to
matched BM counterparts as well as to ILC2s from healthy
individuals (Fig. 2j, k). Consistent with these observations, in vitro
blocking of the NKp30-B7H6 interaction signiﬁcantly inhibited
IL-13 production by ILC2s from APL patients in co-cultures with
APL cells (Fig. 2l, m).
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Fig. 1 ILC2 are signiﬁcantly increased in human APL. a Representative examples of ﬂow cytometry analysis of innate lymphoid cells (ILC) in healthy donors
(HD) and APL patients’ (APL) peripheral blood. HD were sex- and age-matched with APL patients, M:F 12:10 vs. 12:10, median age 45 vs. 43, min 27 vs. 23,
max 72 vs. 77 years. b Frequencies (n= 22) and c cell numbers/µl (HD n= 20, APL n= 13) of total ILCs identiﬁed as Lin−CD127+ cells in lymphocytes.
d Representative examples of ﬂow cytometry analysis of innate lymphoid cell subsets in HD and APL patients’ (APL) peripheral blood. e Relative
frequencies (n= 22) f cell numbers/µl (HD n= 20, APL n= 13) of ILC subsets among total ILCs. g Representative examples of ﬂow cytometry analysis of
ILC subsets in the bone marrow of healthy donors (HD BM) and APL patients (APL BM). h Relative frequencies of ILC subsets among total ILCs (HD n= 5,
APL n= 11). i Representative examples of ﬂow cytometry analysis of ILC subsets in paired APL BM and peripheral blood (APL PB) samples of APL patients.
j Relative frequencies of ILC subsets among total ILCs (n= 11). k Frequency of Ki-67 expressing ILC2 in HD, APL BM and APL PB (n= 11). ILC subsets are
deﬁned as follow: ILC1: Lin−CD127+CRTH2−cKit−; ILC2: Lin−CD127+CRTH2+cKit−/+; ILC3 NCR+: Lin−CD127+CRTH2−cKit+NKp46+; ILC3 NCR−: Lin−CD127+
CRTH2−cKit+NKp46−. Error bars are s.e.m. Statistical analysis was performed using t test (a–f), Mann-Whitney test (h–j) and ANOVA test (k)
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Since ILC2s can be activated by alarmins and PGD2, we
quantiﬁed these mediators in the sera of APL patients at
diagnosis. We found no detectable difference in IL-33, IL-25 or
TSLP concentrations, but PGD2 concentrations were signiﬁcantly
elevated in APL patients compared to healthy donors (Fig. 2n).
To test whether leukaemic cells may be the source of PGD2 in
APL, we cultured the cell lines NB4 and HL60, and the AML cell
lines KG1 and THP1 in presence of arachidonic acid. Only NB4
and HL60 cell lines produced PGD2 (Fig. 2o). Next, we asked
whether PGD2 could further enhance IL-13 production by ILC2
in the presence of APL cell lines. We found that although PGD2
alone can induce IL-13 production in ILC2s, in agreement with
prior reports9, addition of PGD2 further enhances expression
of IL-13 by ILC2s in combination with an APL cell line
(Supplementary Fig. 2c).
To further verify the consistency of our observations, we
retrieved mRNA expression data from The Cancer Genome Atlas
(TCGA) for treatment-naive AML patients, including APL.
TCGA data conﬁrmed the speciﬁc upregulation of PGD synthase
(but not PGE and PGI2), CRTH2 as well as B7H6 (but no other
B7H molecules, except B7H3) in APL as compared to the other
AML subtypes (Supplementary Fig. 2d).
Together, these ﬁndings suggest that circulating ILC2s in
APL patients are primed to secrete IL-13 in response to
malignant cells.
ILC2-derived IL-13 promotes functional M-MDSC. To under-
stand the circuitries established by ILC2s through the secretion of
IL-13, we screened different cell populations from APL patients
and healthy donors for the expression of IL-13Rα1. Strikingly,
CD14+ cells from both APL patients and healthy donors
expressed high levels of this receptor (Fig. 3a, b). Since IL-13 is an
inducer and activator of M-MDSCs, at least in mice35, 54, and
since IL-13 was upregulated in patients, we asked whether the
CD14+ compartment of APL patients was enriched in M-MDSCs.
As assessed by the expression of surface markers (Fig. 3c) and
mRNA levels of arginase-1 and iNOS (Fig. 3d, e), CD14+ cells of
APL patients were strongly enriched in M-MDSCs, and were
present at increased frequencies compared to healthy donors
(Fig. 3f). To further substantiate that ILC2s have direct effects on
M-MDSC induction via IL-13, ILC2s were puriﬁed, expanded
(Supplementary Fig. 3) and then stimulated with PGD2 and the
NB4 APL cell line to secrete IL-13. Cell-free supernatants of these
co-cultures were transferred onto puriﬁed CD14+ cells from
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healthy donors. As shown in Fig. 3g, h, CD14+ cells cultured with
ILC2-derived supernatants upregulated arginase-1 and iNOS,
which were abrogated by an anti-IL-13 blocking antibody.
Importantly, ILC2 supernatant-induced M-MDSCs could
attenuate autologous T-cell proliferation induced by anti-CD3/
CD28 activation, indicating a bona ﬁde suppressor cell functional
phenotype (Fig. 3i, j).
These ﬁndings suggest that ILC2 drive the expansion of
functional M-MDSCs in APL patients via IL-13.
ATRA treatment reverses the increase of ILC2-MDSC in APL.
Collectively, the above ﬁndings suggest a scenario in which APL
blasts trigger the secretion of IL-13 by ILC2s through the com-
bined engagement of CRTH2 by PGD2 and of NKp30 by B7H6,
leading to the expansion and activation of M-MDSCs (Fig. 4a).
To test this hypothesis, we compared each one of the components
of this immunosuppressive axis in APL patients at diagnosis and
in complete remission, upon disappearance of the APL blasts
following ATRA treatment. In primary APL patients’ samples
collected after ATRA treatment, we found normalized levels of
circulating PGD2, normalized presence of NKp30+ ILC2s and of
total ILC2s, and normalized levels of circulating IL-13 and
M-MDSCs (Fig. 4b–f). In agreement with our in vitro data
showing attenuated T-cell proliferation in the presence of
M-MDSCs (Fig. 3i, j), CD8+ T cells from treatment-naive APL
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patients had lower Ki-67 expression and produced less
granzyme B than T cells from patients in remission after ATRA
therapy (Supplementary Fig. 4a, b). These ﬁndings suggest that
complete remission was also accompanied by a recovery of T-cell
functions.
To further explore the dynamics of the immunosuppressive
axis that we have identiﬁed in patients, we used a transplantable
mouse model of APL known to accurately recapitulate the human
disease, including the sensitivity to ATRA26, 27. In this model, the
human t(15;17) translocation that characterizes APL and gives
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rise to the PML-RARA fusion protein is mimicked by the
expression of the PML-RARA transgene in myeloid cells (referred
to as PML-RARA APL mice; Fig. 4g–i). Importantly, in PML-
RARA mice, the establishment of the disease resulted in increased
levels of PGD2, ILC2s and bona ﬁde M-MDSCs (Fig. 4j–l).
Furthermore, achievement of remission following ATRA treat-
ment was accompanied with normalized levels of PGD2, ILC2s
and M-MDSCs as well as with a recovery of activated CD8+
T cells (Fig. 4j–l and Supplementary Fig. 4c–e). To determine if
T cells played a major role in controlling APL engraftment, we
moved to a less aggressive APL mouse model (i.e., APL B6) and
we depleted CD4+ and CD8+ T cells. T-depleted APL B6 mice
showed a shorter survival and an enhancement in ILC2s and M-
MDSCs (Supplementary Fig. 4f–h).
Moreover, to be closer to the human immune system, we
developed a mouse model in which immunodeﬁcient NSG mice
were reconstituted with a human immune system (HIS) and then
injected with a human APL cell line (referred to as HIS APL
mice), to test whether human APL cells had a direct effect on
ILC2 expansion in vivo. APL establishment and clearance were
followed by measuring luciferase intensity (Supplementary Fig. 4i, j).
We observed an enhancement in PGD2 concentration and a
major accumulation of ILC2s and M-MDSCs upon leukaemia
engraftment that were signiﬁcantly reverted by ATRA therapy
(Fig. 4m–q). Importantly, ILC2 and Th2 were able to produce
IL-13 upon in vitro stimulation, but only IL-13 production by
ILC2 was inhibited by ATRA therapy in vivo (Supplementary
Fig. 4k), while NKT cells were barely detectable. By monitoring
cultured ILC2s exposed to ATRA, as well as in vivo ILCs in
control HIS mice upon ATRA treatment we excluded a direct
effect of ATRA on ILC2 (Supplementary Fig. 4l, m), although it
was previously reported by others that ATRA might have a direct
effect on ILC2s, at least in the gut28.
These ﬁndings strongly support the sequence of events initiated
by APL cells in vivo leading to expansion of highly suppressive
M-MDSCs. Thus, this is a novel, ILC2-mediated, tumour
immunosuppressive axis operating both in APL patients and in
APL mouse models.
PGD2/NKp30/ILC2/IL-13 blockade reverts immunosuppression.
To test our hypothesis that ILC2 play a central role in mediating
increased M-MDSC levels upon APL progression, we used the
previously described iCOS-T mouse model29, to temporarily
deplete ILC2s, while maintaining all the T-cell subsets, by the
administration of diphtheria toxin (DTx, Fig. 5a). Also in this
model, APL establishment resulted in ILC2 increase that was
inhibited in the DTx-treated mice (Fig. 5b). Importantly, ILC2-
depleted APL mice showed decreased M-MDSC levels, conﬁrm-
ing a direct link between ILC2 and M-MDSC expansion (Fig. 5c).
According to our results, the binding of PGD2 to CRTH2 and
B7H6 to NKp30 on ILC2 are the initial triggers of the ILC2-IL-
13-M-MDSC immunosuppressive axis in APL. Therefore, to
verify our hypothesis and identify druggable therapeutic targets in
a suitable model, we aimed at blocking the prostaglandin
metabolism in vivo. To do so, PML-RARA APL mice were
treated once a day with indomethacin, a broad inhibitor of
cyclooxygenase (COX) enzymes. As expected, indomethacin
treatment resulted in low levels of PGD2. However, this treatment
had no effect on the increase of ILC2s, most probably because by
blocking COX, indomethacin not only inhibits PGD2, but also
PGI2 synthesis, that was recently shown to downregulate the
frequency and the function of ILC2s12. As a consequence of
sustained ILC2 levels, M-MDSCs in indomethacin-treated mice
remained as high as in untreated animals (Supplementary
Fig. 5a–d). Therefore, we speciﬁcally blocked the PGD2 pathway
by treating PML-RARA APL mice twice a day with TM30089, a
speciﬁc antagonist of the PGD2 receptor. Following this
treatment, PML-RARA APL mice showed low levels of PGD2
and a decrease in ILC2s and M-MDSCs (Supplementary
Fig. 5e–h), demonstrating that the ILC2-M-MDSC immunosup-
pressive axis is partly driven by high PGD2 concentrations acting
upon the CRTH2 receptor on ILC2s.
Since NKp30 does not exist in mice, we then aimed at blocking
both the upstream and the downstream signals (i.e., PGD2 and
IL-13) in PML-RARA APL mice. This combined treatment
resulted in a decrease in PGD2 concentration, ILC2s, M-MDSCs
and in a partial delay in mortality (Fig. 5d–h). Therefore, we
hypothesised that the second signal coming by the APL cells (i.e.,
the binding of B7H6 to NKp30) was important in establishing/
sustaining the immunosuppressive axis. Thus, the only setting
where to test this hypothesis is offered by the APL HIS mice
(in which NKp30 is expressed). In this model, we interfered with
all different signals of the axis by using the PGD2 inhibitor,
a human NKp30 blocking antibody, and an anti-human IL-13
neutralizing antibody (referred to as COMBO) (Fig. 5i).
Following COMBO treatment, APL HIS mice showed reduced
APL cell engraftment as well as a reduction in PGD2, ILC2s and
M-MDSCs. This phenotype was accompanied with a signiﬁcantly
prolonged survival (Fig. 5j–o).
Taken together, our in vivo observations show that disruption of
the novel tumour immunosuppressive axis by speciﬁcally blocking
PGD2, IL-13 and NKp30 at least partially restores immunity
resulting in increased survival in humanized leukaemic mice.
ILC2s and M-MDSCs are enriched in prostate cancer. To test
whether this new immunosuppressive axis was established in
other human tumours, we screened human cell lines derived from
different solid tumours for their ability to secrete PGD2. Among
Fig. 4 ATRA reverses the PGD2-ILC2-IL-13-M-MDSC immunosuppressive axis. a Schematic representation of the hypothetical immunosuppressive chain
established in APL patients at diagnosis. b Comparison of serum concentrations of PGD2 (APL= 11; Rem= 9), c frequencies of ILC2 NKp30+ (APL= 11,
APL Rem= 9), d frequencies of total ILC2 (APL= 22; APL Rem n= 9), e serum concentrations of IL-13 (APL n= 11; APL Rem n= 9) and f frequencies of
M-MDSC (APL n= 22; APL Rem= 9) in peripheral blood of APL patients at diagnosis (APL) or in remission after ATRA treatment (APL Rem). Dashed lines
represent mean values of all the parameters in HD. g Schematic representation of APL establishment and ATRA treatment schedule in FVB/NJ mice upon
injection of APL splenocytes (three independent experiments), as assessed by quantiﬁcation of the normal composition of the bone marrow (Gr1+CD11b+
cells) h, as previously described27. i Survival curves of untreated (APL, n= 13) and ATRA-treated (ATRA) APL mice (n= 6). j Quantiﬁcation of PGD2
concentrations (CTR n= 15, APL n= 13, ATRA day 14 n= 9, ATRA day 25 n= 6), k ILC2 frequencies and l M-MDSCs frequencies in control FVB/NJ mice
(CTR), APL mice before (APL) and after ATRA treatment (ATRA day14; ATRA day25) (CTR n= 12, APL n= 10, ATRA day 14 n= 9, ATRA day 25 n= 6).
m Schematic representation of APL establishment and ATRA treatment schedule in HIS mice upon injection of an APL cell line (two independent
experiments). n Survival curves of untreated (APL, n= 5) and ATRA-treated (ATRA, n= 3) APL HIS mice. o Quantiﬁcation of PGD2 concentrations (CTR
n= 8, APL n= 8, ATRA n= 5), p ILC2 frequencies (CTR n= 11, APL n= 13, ATRA n= 9) and q M-MDSCs frequencies (CTR n= 8, APL n= 8, ATRA n= 5)
in APL HIS mice before (APL) and after ATRA treatment at day 25 (ATRA) (up to two independent experiments). Error bars are s.e.m. Statistical analysis
was performed using Mann-Whitney test (b–f), Kruskal-Wallis test (h, j–l, o–q) and Log-rank test (Mantel-Cox) (i, n)
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several cell lines, including colon, liver and kidney cancer cell
lines, the established prostate cancer cell lines DU145 and PC3
produced the highest levels of PGD2 (Fig. 6a). Next, we assessed if
these cell lines also expressed the NKp30 ligand B7H6. Similarly
to APL blasts, prostate cancer cell lines expressed high levels of
B7H6 (Fig. 6b). Then, we evaluated peripheral blood samples of
patients suffering from prostate cancer for ILC subset distribution
and M-MDSC frequencies. Importantly, we found enrichment in
ILC2s and NKp30+ ILC2s in patients as compared to healthy
donors (Fig. 6c, d) as well as increased frequencies of M-MDSCs,
as shown in Fig. 6e. In periphery, no correlation was found
between ILC2 and M-MDSC. However, ILC2 enrichment was
stage dependent (Fig. 6f) and was not apparent in samples from
patients with benign prostate hypertrophy.
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h Survival curves of untreated (APL) and PGD2i + αIL-13-treated FVB/NJ mice injected with APL blasts (APL n= 12, PGD2i + αIL-13 n= 12). i Schematic
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leukaemic engraftment (n= 8). l Quantiﬁcation of PGD2 concentrations (n= 8), m ILC2 frequencies (APL n= 13, COMBO n= 8) and n M-MDSCs
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antibody (COMBO) (n= 8). o Survival curves of untreated APL HIS mice and APL HIS mice treated with PGD2 inhibitor (TM30089), anti-NKp30 blocking
antibody and anti-IL-13 neutralizing antibody (COMBO; n= 5). Error bars are s.e.m. Statistical analysis was performed using Kruskal-Wallis test (b, c),
Mann-Whitney test (e–g, k, l–n) and Log-rank test (Mantel-Cox) (h, o)
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Given the inaccessibility to human prostate tumour specimens,
we used a mouse model in which mice uniformly and
spontaneously develop autochthonous (orthotopic) prostate
tumours following the onset of puberty (referred to as TRAMP
mice)30. In agreement with our observations in patients, we found
that ILC2s were increased in the blood of TRAMP mice as
compared to the blood of female mice of the same strain (FVB).
Notably, in paired spleen and prostate samples of TRAMP mice,
ILC2s were highly enriched within the prostate tumours (Fig. 6g, h).
Thus, we assessed the presence of M-MDSCs in the same
tumours and observed that M-MDSCs frequencies positively
correlated with tumour-inﬁltrating ILC2s (Fig. 6i). In addition,
we quantiﬁed T, NKT, B cells, as well as eosinophils in the
prostate, blood and spleen of tumour-free and tumour-bearing
TRAMP mice (i.e., before and after 12 weeks of age) and we
found no difference in the blood and in the spleen. However,
in the prostate, beside the enhancement in M-MDSCs
already described above, we found a reduction of NKT cells
(Supplementary Fig. 6a–c).
Overall, these data in prostate cancer, although only correla-
tive, suggest that the expansion in M-MDSCs within the tumour
might be driven by the increase in ILC2s responding to tumour-
secreted PGD2.
Discussion
In this study, by combining the analysis of primary APL patients’
samples and in vivo APL models, we have uncovered a novel
tumour immunosuppressive axis initiated by malignant cells.
Our data are consistent with a sequence of events driven by
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tumour-derived PGD2 associated with engagement of the
NKp30-B7H6 pathway leading to signiﬁcant ILC2 activation and
expansion. In turn, increased IL-13 secretion by primed ILC2s
results in a signiﬁcant expansion of activated M-MDSCs, which
may inhibit anti-tumour immune responses. We show that
in vivo interference with PGD2, NKp30 and IL-13 functions
in murine and humanized APL models is sufﬁcient to sig-
niﬁcantly reverse immunosuppression and increase survival of
humanized tumour-bearing mice. These data demonstrate
unprecedented ILC2-mediated tumour immunosuppression in
human malignancies.
Arachidonic acid catabolism by cyclooxygenase enzymes and
speciﬁc synthases is dysregulated in a number of tumours,
including pancreatic, lung, breast, colon, prostate and bladder
cancer, due either to the overexpression of cyclooxygenases and
prostaglandin synthase enzymes23, 31–33, or by dysfunctions of the
prostaglandin degrading enzymes, leading to an accumulation of
intermediate metabolites34. Recently, some members of the PG
family, namely PGI2, PGD2 and PGE2, have emerged as key
regulators of ILC2 and ILC3 functions and systemic inﬂamma-
tion9, 12, 35. Yet, nothing is known on the role of PG on ILC
functions in anti-tumour immunity. We document for the ﬁrst
time a correlation between tumour-derived PGD2 and ILC2
accumulation in cancer patients. The observation, that CD4+ Th2
and NKT cells are unaltered in APL patients compared to con-
trols, suggests that PGD2 signalling acts on ILC2s in a T-cell-
independent manner. In that regard, the increased expression of
NKp30 on patients’ ILC2s and of B7H6 on malignant APL blasts
might act as second indispensable signal for a speciﬁc ILC2
activation. NCR engagement was already shown to be crucial in
the context of human lung cancer, where the expression of
another NCR, NKp44, by ILC3 NCR+ was shown to promote
formation of tertiary lymphoid structures36. Here in contrast to
the protective role of NKp44 ligation on ILC3, NKp30 triggering
on APL patients’ ILC2s favours the release of large quantities of
IL-13 that has been recently shown, at least in mice, to promote
M-MDSC activation and expansion35, 54.
Elevated serum IL-13 concentrations correlating with increased
M-MDSC levels have been reported in patients with different
solid tumours37. Yet, the source of IL-13 was considered to be
CD4+ Th2 cells or malignant cells. This paradigm has recently
been revisited in the context of type 2 immunity in infectious
diseases, asthma and skin autoimmunity, where ILC2s appear
to be the initial source of IL-13, acting as indispensable con-
tributors for efﬁcient pathogen clearance29, 38 and pathology
development14, respectively. In the context of APL, we show that
antigen-independent IL-13 secretion by ILC2s is pivotal for the
functionality of M-MDSCs39. Moreover, in haematologic malig-
nancies, IL-13 was reported to also exert pro-tumoural activity on
mesenchymal stromal cells40, an observation that warrants fur-
ther veriﬁcation in other types of tumours.
M-MDSCs may exert their immunosuppressive functions
through different mechanisms. They were shown to promote
induction of regulatory T cells (Treg)41, however this component
does not seem to be the predominant one in APL, since
Treg levels in patients were normal (Supplementary Fig. 2a).
Rather, we speculate that by iNOS and arginase-1 upregulation,
M-MDSCs act on effector cells, by inhibiting T and NK cell
functions, thus impairing efﬁcient leukaemic cell clearance42.
The unique diagnostic and therapeutic setting of APL allowed
us to follow the newly identiﬁed immunosuppressive axis in
patients from disease onset to complete remission. In agreement
with our hypothesis, ATRA-induced differentiation and eventual
death of malignant APL blasts resulted in a normalization of
PGD2 levels, as well as a complete restoration of all downstream
mediators of the pathway (i.e., ILC2s, NKp30, IL-13, M-MDSCs,
T-cell effector functions). In our APL mouse models, beside the
use of ATRA, we tested a broad blocker of COX (indomethacin),
as well as a speciﬁc PGD2 inhibitor (TM30089). Only the latter
showed a partial resolution of the immunosuppressive axis,
probably due to the fact that other PG metabolites exert opposite
effects on speciﬁc ILC subsets. Indeed, it was recently reported
that PGI2 inhibits ILC2s, while PGE2 directly acts on ILC3s by
promoting their anti-inﬂammatory function12, 35. As further
proof of the involvement of IL-13-producing NKp30+ILC2s in
directly controlling activation and expansion of M-MDSCs in our
models, we used temporally ILC2-depleted iCOS-T mice injected
with leukaemic cells and showed that a loss in ILC2s results in a
decrease of M-MDSCs. To be closer to a therapeutic setting in
patients, where ILC2 depletion might not be a feasible option, we
combined inhibition of PGD2 with NKp30 and IL-13 blocking
antibodies. The treatment resulted in partial normalization of the
axis and increased survival in both models used. Due to the lack
of NKp30 expression in mice, it will be highly important to
further test the clinical relevance of our observations in NSG
and HIS mice transferred with human APL cell line expressing
PML-RARA fusion protein or human primary APL blasts, to
provide additional mechanistic clues. However, in contrast to
other AML subtypes, engraftment of primary APL is documented
to be poor43. Once established, these models would be valuable
tools for future in vivo testing of treatment options of ILC2
modulators, for rapid translation to the clinics.
In that context, the importance of therapeutically correcting
immunosuppressive barriers in cancer patients has been recently
highlighted by the impressive clinical results of immune check-
point blockade using monoclonal antibodies against CTLA-4 and
PD1/PDL144. Thus, the novel immunosuppressive axis that we
characterized in APL might be targetable in patients with solid
tumours of different histological types for which the beneﬁt of
current therapies is still unsatisfactory. Indeed, in human
tumours with altered arachidonic acid catabolism or exaggerated
alarmin production (e.g., IL-3345), the ILC2-IL-13-M-MDSC
network might represent a novel, early acting innate pathway of
immune regulation.
In conclusion, we show that ILC2s may be considered a novel
modulator of tumour immunosuppressive networks that can
connect signals derived from tumour cells with tolerogenic cells
that facilitate tumour growth.
Methods
Human cell collection. Venous blood was drawn from healthy donors at the local
Blood Transfusion Center, Lausanne, Switzerland, under the approval of the
Lausanne University Hospital’s Institute Review Board. Peripheral blood and BM
samples were obtained from patients with PML-RARα-positive acute promyelo-
cytic leukaemia, at diagnosis (n= 22) or during remission after ATRA treatment
(n= 9), from treatment-naive patients with prostate adenocarcinoma (n= 21)
and benign prostate hypertrophy (n= 5) at clinical centres in Bologna, Milano,
Rozzano, Lausanne, Bern, Bergamo and Padova. The study was approved by the
Institutional Review Boards of the University Hospital of Bologna, the San Raffaele
Hospital, the Humanitas Research Hospital, the Lausanne University Hospital, the
Bern University Hospital, the Hospital of Bergamo and Padova (EC consents:
EMATC-2013-01, EC 1720, EC 11-09-2006, APL01, 1237-25090 and 119/10).
Written informed consent was obtained from all healthy subjects and patients, in
accordance with the Declaration of Helsinki. Fresh anticoagulated blood diluted at
1:2 ratio in PBS was layered on lymphoprep (ratio diluted blood: lymphoprep
1.5:1). Mononuclear cells were isolated by density gradient centrifugation (1800
rpm, 20 min centrifugation without break, room temperature), washed and
immediately cryopreserved in 50% RPMI, 40% FCS and 10% DMSO. Serum
samples were also collected at the same sampling day after centrifugation of whole
blood at 2000 rpm for 10 min, at room temperature, and immediately frozen. Of
the 22 APL patients, for in vitro and ex vivo assays, we selected samples exclusively
according to cell viability (more than 70% living cells) and counts (more than 1 ×
106 living cells) upon thawing.
Cell culture. Human leukaemic lines (KG1, catalogue number (cn): CCL-246,
ATTC; THP1, cn: TIB-202, ATCC, HL60, cn: CCL-240, ATCC; NB4, cn: ACC207,
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DSMZ)26, lung adenocarcinoma (A549, cn: CCL-185, ATCC), malignant mela-
noma (Me275, derived in-house, Ludwig Institute for Cancer Research, Lausanne
Branch, Lausanne, Switzerland), breast (MDA-MB-231, cn: CRM-HTB-26,
ATCC), ovarian (HeLa, cn: CCL-2, ATCC), colon (HCT116, cn: CCL-247, ATCC),
liver (HepG2, cn: HB-8065, ATCC), kidney (A-498, cn: HTB-44, ATCC) and
prostate cancer (DU145, cn: HTB-81, ATCC and PC3, cn: CRL-1435, ATCC) cell
lines were owned to the host laboratory and maintained in tissue culture ﬂasks in
RPMI supplemented with 10% FCS, amino acids and HEPES. All cell lines were
periodically tested for mycoplasma contamination and conﬁrmed negative by PCR
with mycoplasma-speciﬁc primers (5′-ACTCCTACGGGAGGCAGCAGTA-3′ and
5′-TGCACCATCTGTCACTCTGTTAACCTC-3′). When indicated, tumour cell
lines were cultured at 1 × 106 cells/ml for 4 h in the presence of 30 μM arachidonic
acid (Sigma).
Human peripheral blood mononuclear cells were cultured in RPMI
supplemented with 8% heat-inactivated, pooled human serum, in the presence of
20 U/ml rhIL2 (Proleukin, Roche). When indicated, PGD2 (Sigma), IL-33
(Adipogen), ATRA (Sigma), anti-human NKp30 or anti-human IL-13 blocking
antibodies, or Ig controls were added. Human ILC2 cell lines were established from
PBMCs by ﬂow cytometry-based sorting of Lin−, CD45+, CD127+, CRTH2+ and
CD161+ after depletion of CD3+ (Microbeads, cn: 130-050-101), CD19+
(Microbeads, cn: 130-050-301), CD14+ (Microbeads, cn: 130-050-201) cells by
AutoMACS (Supplementary Fig. 3). ILC2 cell lines were expanded in Yssel’s
medium supplemented with 1% AB human serum, with irradiated (dose: 30 Gy,
source: CS-137) allogenic PBMCs and 100 U/ml rhIL2 for 3 weeks.
For in vitro experiments using CD14+ cells, pure ILC2 cell lines were
co-cultured with the NB4 APL cell line at a 1:1 ratio and 100 nM PGD2 for 48 h.
Cell-free supernatants were added to magnetically puriﬁed CD14+ cells maintained
in 10 ng/ml GM-CSF, in the presence or absence of 10 μg/ml anti-IL-13
neutralizing antibody, an Ig control or recombinant human IL-13 (BioLegend) for
6 days, as indicated. cDNA was extracted from CD14+ and processed as described
below.
For in vitro proliferation assays, CD14+ cells (human), cultured in the presence
or absence of ILC2-conditioned supernatants, or CD11b+Gr1dim (mouse) cells
were co-incubated at 1:1 ratio with magnetically enriched CD3+ T cells, previously
labelled with CFSE. Proliferation of CD3+ T cells stimulated with plate bound anti-
CD3 and soluble anti-CD28 antibodies (1 μg/ml each) was assessed after 4 days by
measurement of CFSE dilution by ﬂow cytometry.
APL model in FVB/NJ background. Murine cells carrying the PML/RARα
translocation (PML-RARA APL cells) were transplanted as reported26, 42, 46.
Brieﬂy, 15 × 106 live cells from spleens of animals with leukaemia were intrave-
nously (i.v.) transferred in 200 μl PBS into previously irradiated (dose: 3,5 Gy,
source: CS-137) FVB/NJ mice that are bred in-house and maintained into a barrier
animal facility. For secondary transplantation, 1.5 × 106 live cells from primary
recipients’ spleens were i.v. transferred into non-irradiated syngeneic mice. In each
experiment PML-RARA APL cells from a single primary recipient were used to
generate all secondary recipients and secondary recipients were used for all
treatments. ATRA (Sigma) (65 mg/kg body weight, i.p.) was administered from day
9 to 12. TM30089 (Cayman Chemicals) (5 mg/kg body weight) was administered
orally, twice a day. Anti-IL-13 antibody (150 μg/mouse/dose) was administrated
every 5 days intraperitoneally (i.p.). Indomethacin (Sigma) (2 mg/kg body weight)
was orally administered once a day. Female mice between 7 and 15 weeks old kept
in a barrier animal facility were randomly assigned to speciﬁc treatment groups,
and the investigator was blinded to the group allocation. Animals were monitored
three times per week during the experiment and clinical signs of disease were
assessed by the presence of blast cells by May-Grünwald-Giemsa staining in blood
smears. At the end of the experiment, mice were killed by CO2 inhalation. This
study was approved by the local Veterinary Authority (VD Service de la con-
summation et des affaires Vétérinaires) under the licence VD1850 and performed
in accordance with Swiss ethical guidelines.
APL model in C57BL/6 background. iCOS-T mice from 6 to 12 weeks old were
kindly provided by Dr Andrew McKenzie from MRC-LMB in Cambridge (UK)
and WT C57BL/6JOLaHsd matching-aged female mice were purchased from
Envigo (stock number: 5704F). In order to deplete ILC2, iCOS-T mice were
injected i.p. with 1 μg of diphtheria toxin (Sigma) for three consecutive days at days
(i) −3, −2, −1, (ii) 25, 26, 27 and (iii) 48, 49, 50.
In a second cohort, WT mice were depleted from CD4+ and CD8+ T cells.
Brieﬂy, at day −2, mice were injected with 400 μg/mouse of anti-CD4 (GK1.5) and
200 μg/mouse anti-CD8 (53-6.7). Then anti-CD4 (200 μg/mouse/dose) and anti-
CD8 (100 μg/mouse/dose) were injected every 5 days until the end of the
experiment. At day 0, 1 × 106 APL cells were transferred i.v. into the tail vein; bone
morrow was monitored at days −1, 29, 49 and at the end of the experiment. This
experiment followed the local Veterinary Authority (VD Service de la
consummation et des affaires Vétérinaires) under the licence VD1850 and Swiss
ethical guidelines.
TRAMP mouse model. Blood, prostate and spleen were collected from 12- to
18-week-old male TRAMP-FVB/NJ mice30 or control female FVB/NJ mice (blood
only). TRAMP-FVB/NJ mice are bread in-house and kept in in our barrier animal
facility. For immune cell isolation, prostate tissue was cut into small pieces in
dissociation medium containing 100 U/ml collagenase and 100 µl/ml DNAse.
Samples were then incubated under agitation at 37 °C during 1 h 15 min. After
ﬁltration through a 0.70 µm nylon ﬁlter, samples were centrifuged and washed with
PBS prior to staining. Animals were monitored three times per week during the
experiment for clinical signs of disease starting at week 14. At the end of the
experiment, mice were killed by CO2 inhalation. This study was approved by the
local Veterinary Authority (VD Service de la consummation et des affaires
Vétérinaires) under the licence VD1850 and performed in accordance with Swiss
ethical guidelines.
Humanized mouse model. Humanized mice (HIS mice) were generated in our
laboratory. Brieﬂy, immune-deﬁcient NSG (NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ) mice
were injected intrahepatically with 100,000 human CD34+ hematopoietic stem cells
(HSC) and analysed for human immune cell reconstitution after 12 weeks using
multi-colour antibody panels established for immune-phenotyping of human
whole blood samples as described47, with some minor modiﬁcations to include ILC
reconstitution (Lin−CD127+ cells). Once reconstituted, 12–14 weeks post trans-
plantation, HIS mice, either males or females, were i.v. injected with enhanced
luciferase48 transfected HL60 APL cells previously tested for mycoplasma con-
tamination (2.5 × 106 live cells/mouse). ATRA (Sigma) (65 mg/kg body weight, i.p.)
was administered daily from day 21 to 24. Hundred and ﬁfty μg/mouse/dose of
anti-NKp30 and anti-IL-13 were injected every 5 days; to monitor leukaemia
progression and treatment effectiveness, mice were injected with luciferin
(3 mg/mouse) at days 7, 17, 25. Images were taken in the Xenogen Ivis 100 in vivo
Imaging System 20 min after the injection (60 s, Bin4, F/Stop 1,2). Animals were
randomly assigned to speciﬁc treatment groups, and the investigator was blinded to
the group allocation. Human CD34+ cells were purchased from either Lonza (CH)
or AllCells (USA). NSG mice were purchased from The Jackson Laboratory (stock
number: 005557) and bred, treated and maintained under pathogen-free conditions
in-house. Animal experimentation followed protocols approved by the local
Veterinary Authority (VD Service de la consummation et des affaires Vétérinaires)
under the licence VD2797 and performed in accordance with Swiss ethical
guidelines.
Antibodies for ﬂow cytometry on human cells. Human ILCs were identiﬁed as
Lineage (FITC-conjugated anti-CD3 (cn: A07746, 1:50), anti-CD4 (cn: A07750,
2:50), anti-CD14 (cn: B36297, 1:100), anti-CD16 (cn: B49215, 1:100), anti-CD19
(cn: 07768, 1:100) (Beckman Coulter), anti-CD8 (cn: MCA1226F, 1:50), anti-CD15
(cn: MCA2458F, 2:50) (AbD Serotech), anti-CD20 (cn: 302304, 1:100), anti-CD33
(cn: 303304, 1:50), anti-CD34 (cn: 343604, 1:100), anti-CD203c (cn: 324614, 1:50)
and anti-FcεRI (cn: 334608, 2:50) (Biolegend)) negative CD127+ (PerCP-Cy5.5-
(cn: 3151322, 1:100) or Brillant Violet 421-conjugated (cn: 351310, 1:100) anti-
CD127 (BioLegend) lymphocytes. ILC subsets were identiﬁed using PE CF594- (cn:
563501, 1:100) or Brillant Violet 421-conjugated (cn: 562992, 2:50) anti-CRTH2
(BD Pharmingen); PerCP-Cy5.5- (cn: 331920, 1:100) or PE-Cy7-conjugated (cn:
562101, 1:100) anti-NKp46 (BioLegend, BD Pharmingen); PE- (cn: 313204, 1:100)
or APC-conjugated (cn: 550412, 1:50) anti-cKit (BioLegend, BD Pharmingen);
APC-eFluor780-conjugated anti-CD56 (cn: 47-0567-42, 2:50 eBioscience). Dead
cells were always excluded using a ViViD LIVE/DEAD ﬁxable dead cell stain kit
(cn: L34957, LifeTechnologies) (Supplementary Fig. 1a). Where indicated, addi-
tional markers were evaluated using a puriﬁed anti-B7H6 antibody (cn: ab121794,
1:100, Abcam) and an AlexaFluor647-conjugated donkey anti-rabbit secondary
antibody (cn: A31573, 1:4000, Life Technologies), PE-conjugated anti-NKp30 (cn:
12-3379-42, 1:100, eBioscience), AlexaFluor647-conjugated anti-Ki-67 (cn: 350510,
1:100, BioLegend), FITC-conjugated anti-Bcl-2 (cn: 340575, 2:50, BD Pharmingen),
FITC-conjugated anti-Granzyme B (cn: 515403, 2:50, BioLegend) antibodies,
PE-conjugated anti-6B11 (cn: 552825, 4:50, BD Pharmingen), PE-Cy7-conjugated
CD1a (cn: 25-0019, 1:50, eBioscience), APC-Cy7-conjugated anti-CD5 (cn: 364009,
1:100, BioLegend), PE-conjugated anti-human TCRαβ (cn: A39499, 2:50, Beckman
Coulter) and PE-conjugated anti-TCRγδ (cn: 331209, 2:50, BioLegend).
Human M-MDSCs were identiﬁed using Paciﬁc Blue-conjugated anti-CD14
(cn: 301816, 2:50, BioLegend), PerCP-Cy5.5-conjugated anti-CD15 (cn: 323020,
1:50, BioLegend), APCeFuor780-conjugated anti-CD11b (cn: 47-0118, 1:50,
eBioscience), APC-conjugated anti-CD33 (cn: 303408, 1:50, BioLegend),
PE-Cy7-conjugated anti-HLA-DR (cn: 307616, 2:50, BioLegend), PE-conjugated
anti-IL-13Rα1 (cn: FAB1462P, 1:50, R&D Systems) and Lineage markers
(PE-AF610-conjugated anti-CD3 (cn: MHCD0322 1:100), PE-AF610-conjugated
anti-CD19 (cn: MHCD1922, 1:50) and PE-TexasRed-conjugated anti-CD56
(cn: MHCD5617, 1:100, all from Invitrogen).
For cytokine production, MNCs were stimulated ex vivo for 3 h with
PMA/ionomycin or were co-cultured with APL cell lines overnight at a 1:1 ratio, in
the presence or absence of PGD2, anti-NKp30 antibody (F525) or an IgM control.
BrefeldinA was added at 2.5 μg/ml after 1 h of co-culture. Intracellular staining was
performed using PE-Cy7-conjugated IFN-γ (cn: 557844, 1:200), APC-conjugated
anti-IL-13 (cn: 561162, 1:100) (both from BD Pharmingen) and AlexaFluor700-
conjugated anti-IL-17A (cn: 512318, 1:100, BioLegend) after ﬁxation and
permeabilization with 0.1% saponin (Sigma). Samples were acquired on a Gallios
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ﬂow cytometer (Beckman Coulter) and data were analysed using FlowJo software
(TreeStar).
Antibodies for ﬂow cytometry on mouse cells. Murine ILCs were identiﬁed as
Lineage (FITC-conjugated anti-CD3e (cn: 130-102-207, 1:200), anti-CD5 (cn: 130-
106-202, 1:200), anti-CD11b (cn: 130-098-085, 1:200), anti-CD11c (cn: 130-102-
466, 1:200), anti-CD19 (cn: 130-102-494, 1:200), anti-Ter119 (cn: 130-102-257,
1:200), anti-B220 (cn: 130-102-228, 1:200), anti-TCRγδ (cn: 130-109-796, 1:200),
anti-DX5 (cn: 130-102-258, 1:200), anti-FcεRI (cn: 130-102-264, 1:50) (all from
Miltenyi Biotec)) negative, CD127+ (eF660 anti-CD127 (clone: A7R34, 1:100,
eBioscience)), CD45+ (PE-Cy7-conjugated anti-CD45 (clone: 30F11, 1:300, Bio-
Legend)) lymphocytes. ILC subsets were identiﬁed using PE-conjugated anti-ST2
(cn: 145304, 1:100, Biolegend); Brilliant Violet 421-conjugated anti-NKp46 (cn:
130-102-185, 1:50, Miltenyi Biotec); PerCP-eFluor710-conjugated anti-cKit (clone:
2B8, 1:200, eBioscience).
Murine M-MDSCs were identiﬁed using PE-Cy7-conjugated anti-CD45 (clone:
30F11, 1:300, BioLegend), AlexaFluor700-conjugated anti-CD11b (clone: M1/70,
1:300, eBioscience) APC-eFluor780-conjugated anti-Gr1 (clone: RB6 AC5, 1:500,
BD Pharmingen), APC-eFluor780-conjugated anti-Ly6C (cn: 47-5932-80, 1:600,
eBioscience), PerCP-Cy5.5-conjugated anti-Ly6G (cn: 45-5931-80, 1:600,
eBioscience) and PE-Cy7-conjugated anti-CD49d (clone 9F10, 1:200, BioLegend)
antibodies, as previously described49, 50.
Additional antibodies used were Paciﬁc Blue-conjugated anti-CD44 (clone:
IM781, 1:100), Alexa647-conjugated anti-CD62L (clone: Mel14, 1:1000),
TexasRed-conjugated anti-B220 (cn:551489, 1:50, BD Pharmingen) and Brilliant
Violet 421-conjugated anti-SiglecF (cn: 565934, 1:200, BD Pharmingen) antibodies.
cDNA synthesis and qRT-PCR. Dry pellets of CD14+ cells from healthy donors or
APL patients and in vitro-induced M-MDSC were resuspended in a lysis/cDNA
mix solution containing 6.3 μl of “lysis buffer” (prepared as previously described by
Gupta et al.51), 3 μl of “5× RT buffer”51, 1.5 μl of 0.1 M DTT (AppliChem), 0.75 μl
of 10 mM dNTPs (Invitrogen), 0.25 μl of 100 ng/μl oligo-(dT) (Metabion), 0.4 μl of
MMLV reverse transcriptase (Invitrogen), 0.2 μl of RNAsin (Promega) and 2.6 μl
RNAse free water. To allow reverse transcription into cDNA, samples were incu-
bated at 37 °C for 60 min. The transcriptase was then inactivated at 90 °C for 3 min
and samples were stored at −80 °C. Quantitative real-time PCR was performed
using KAPA SYBR® FAST master mix with ROX (KAPA Biosystems), 200 nM of
each primer and 1/50 of the reverse transcription reaction. Samples were run at
least in duplicate in a ABI 7500 Fast Real-Time PCR thermocycler (Applied Bio-
systems) with the following parameters: 3 min at 95 °C for enzyme activation, 40
cycles at 95 °C for 5 s and 60 °C for 30 s, followed by amplicon melting analysis to
evaluate the speciﬁcity of the reaction and identify the presence of primer-dimers.
Primers sequences were as follows: for GAPDH, 5′-GGACCTGACCCTGCCGTC
TAG-3′ (forward) and 5′-CCACCACCCTGTTGCTGTAG-3′ (reverse); for argi-
nase-1: 5′-ATTCTTCCGTTCTTCTTGACTT-3′ (forward) and 5′-AGTGTGATG
TGAAGGATTATG-3′ (reverse); for iNOS: 5′-ATGCTCAGCTCATCCGCTAT-3′
(forward) and 5′-CACAAGGTCAGGTGGGATTT-3′ (reverse); and were pur-
chased from Microsynth (Switzerland). Results were normalized to GAPDH and
expressed as 2−ΔCt.
ELISA. Human IL-13 ELISA (cn: 435207, Biolegend), mouse IL-13 ELISA (cn: 88-
7137-22, eBioscience), human IL-33 (cn: 435907, Biolegend), human IL-25 ELISA
(cn: KA2190, Abnova), human TSLP ELISA (cn: 434207, Biolegend), PGD2-MOX
ELISA (cn: 512011, Cayman Chemicals) were performed according to the manu-
facturer’s instructions. Human IL-4 and IL-17 were quantiﬁed using V-Plex
Proinﬂammatory Panel 1 (human) Kit (cn: K15049D, Meso Scale Discovery),
according to the manufacturer’s instruction.
Computational analysis on TCGA data. Gene expression from acute myeloid
leukaemia patients from TCGA (The Cancer Genome Atlas)52 were obtained
through the release 18 of ICGC (the International Cancer Genome Consortium,
https://icgc.org/ data set name “LAML-US”). The downloaded raw read counts
(RNASeqV2_RSEM_genes data) was normalized to log2-counts per million with
help of the functions calcNormFactors from the R package edgeR version 3.12.053
and voom from the R package limma version 3.26.354.
Statistical analyses. Statistical analysis was performed using t tests or ANOVAs
or the equivalent non-parametric (Mann-Whitney or Kruskal-Wallis tests) tests
when data were not normally distributed (as assessed with Kolmogorov-Smirnov
test of normality and Levene’s test for homogeneity of variance). Dunnett cor-
rection was eventually used for multiple comparisons. Data are shown by plotting
individual data points and the mean ± s.e.m. A p value less than 0.05 (two-tailed)
was considered as statistically signiﬁcant and labelled with *. p values less than 0.01,
0.001 or 0.0001 were labelled respectively with **, *** or ****. Sample size was
estimated with G*power software in order to obtain relevant statistical analysis
(p< 0.05) with a power ≥ 0.8. For human experiments, the effect size was derived
based on our previously published cohort of AML patients22 focusing on ILC3
NCR+ frequencies in patients vs. HD (d = 1.79). Thus, we estimated a minimum
sample size of 10 patients at diagnosis and of 4 patients in remission (d= 3.22).
For mice experiments, the effect size was estimated based on a pilot experiment
comparing ILC2 increase between PML-RARA APL mice and CTR mice
(d= 3.06). Thus, we predicted that each group had to contain at least four mice
per group. Mice developing unrelated diseases were excluded from the analysis.
Statistical analysis of survival curves was performed with Log-rank (Mantel-Cox)
test.
Data availability. The authors declare that all data supporting the ﬁndings of this
study are available within the article and its Supplementary Information ﬁles or
from the corresponding authors on reasonable request.
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